Skip to main content
Equibles
ADTX logo

ADTX · Aditxt, Inc. · Metrics

Track ADTX — free

Use ADTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 -0.01 (-80.00%) At close · Jun 25
Rebalance outlook locked
Going-concern doubt — flagged May 20, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because of these factors, we believe that this creates substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed May 20, 2026
Market Cap
$4.99M
Shares
815,921
Volume · Jun 25 362.99M Avg daily vol (27 sessions) 900.84M

ADTX metrics

42 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$4.99M

Price action

20 metrics
Price change (1W)
-80.0%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
4.3
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
900.84M
Relative volume
0.4
Average dollar volume
$16.96M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
815,921

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 8,306,454,000.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
348.1×
reciprocal yield 0.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,066.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
19.9%
Operating margin
-127,821.4%
Trailing 12 months
Net margin
-371,093.9%
Gross profit (TTM)
$2,852
Operating profit (TTM)
−$18.32M
Net income (TTM)
−$53.20M
Trailing 12 months
Diluted EPS (TTM)
$166,129.08
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$366.74

Growth

11 metrics
Revenue growth YoY
+1,094.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$14,336
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+69,465.5%
Year over year · more shares
Revenue CAGR (3Y)
-84.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-382.5%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-33.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$268,852
Total assets
$13.91M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$18.55M
Capital expenditures (TTM)
—
R&D (TTM)
$3.03M
SG&A (TTM)
$1.15M
Stock compensation (TTM)
—
R&D / revenue
21,149.6%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
-8
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-95.0%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1726711 CUSIP 007025869 Visit website